Brief: Antengene Announces Approval Of IND Application In China For Phase 3 Clinical Trial Of ATG-010
18/12/2020 06:29
Dec 18 (Reuters) - Antengene Corp Ltd 6996.HK :
* ANNOUNCES APPROVAL OF INVESTIGATIONAL NEW DRUG APPLICATION
IN
CHINA FOR A PHASE 3 CLINICAL TRIAL OF ATG-010 (SELINEXOR)
* APPROVAL FOR PHASE 3 CLINICAL TRIAL OF ATG-010 (SELINEXOR)
FOR
TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA
Source text for Eikon: urn:newsml:reuters.com:*:nHKS2G538Z
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106